About
Neurimmune is a biopharmaceutical company dedicated to the development of immunotherapeutics for the treatment and prevention of human disorders with high unmet medical needs. With its unique Reverse Translational Medicine™ platform, Neurimmune creates recombinant human-derived monoclonal antibodies with biophysical characteristics closely resembling those occurring in healthy elderly. These antibodies display unique properties such as target selectivity, superior pharmacodynamics and low immunogenicity, resulting in superior risk profiles and excellent efficacy. Neurimmune’s pipeline comprises programs for a broad variety of disease related targets and specific target conformations. These include misfolded, oligomeric, fibrillar or post-translationally modified forms of disease-associated proteins as well as physiological conformations involved in major disease pathways.
Position in the VCSift Database
- • 4,609 investors in VCSift focus on the biotech sector.
- • 8 investors are based in Schlieren, Zurich, Switzerland.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Sectors
- biotech
- Location
- Schlieren, Switzerland
Contact Information
Find more investors like Neurimmune
Search Investors